Hodgkin’s Lymphoma Treatment Market – Global
Industry Insights, Trends, Outlook, and Opportunity
Analysis, 2019 – 2027
Lymphoma is a cancer caused in lymphocytes of the body, i.e. white blood cells. It is of two
types – Hodgkin’s Lymphoma and Non-Hodgkin’s Lymphoma. Hodgkin’s Lymphoma can be
characterized into two categories – classic and nodular lymphocyte predominant. Some of the
signs indicating presence of Hodgkin’s Lymphoma in the body is fever, sudden weight loss, and
swollen lymph nodes. Hodgkin’s Lymphoma is mostly treated with chemotherapy alone or with
the combination of radiotherapy.
Request Sample Copy of Research Report @ http://bit.ly/30SYZhP
Global Hodgkin’s Lymphoma Treatment Market Drivers
Approvals of the drugs by regulatory bodies for the treatment of Hodgkin’s lymphoma is
expected to drive the global Hodgkin’s lymphoma market growth. In 2018, Seattle Genetics,
Inc. received the Health Canada approval for its supplemental New Drug Submission that
expands the use of Adcetris (brentuximab vedotin) in combination with AVD (Adriamycin,
vinblastine and dacarbazine) chemotherapy in patients with previously untreated Stage IV
Hodgkin lymphoma (HL). Adcetris is indicated for the treatment of adult patients with
previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with
doxorubicin, vinblastine, and dacarbazine.
Furthermore, key players are constantly trying to expand the indications of their already
approved drug. For instance, in March 2017, Merck & Co. Inc. received an approval by U.S.
Food & Drug Administration (FDA) of the drug, Keytruda for the treatment of classical
Hodgkin’s lymphoma. It is approved on the basis of response durability and tumor response
rate and is supposed to be administered intravenously into patients. It was originally approved
in 2014. Such frequent approvals of drugs by regulatory bodies are expected to impact
positively on the global Hodgkin’s lymphoma treatment market growth.